

Giuseppe Bruno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/932527/publications.pdf>

Version: 2024-02-01

93
papers

2,729
citations

147801

31
h-index

214800

47
g-index

94
all docs

94
docs citations

94
times ranked

4434
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of frailty in Parkinsonâ€™s disease: a cross-sectional study. <i>Journal of Neurology</i> , 2022, 269, 3006-3014.	3.6	7
2	Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1467-1474.	2.6	2
3	Biomarkers and phenotypic expression in Alzheimerâ€™s disease: exploring the contribution of frailty in the Alzheimerâ€™s Disease Neuroimaging Initiative. <i>GeroScience</i> , 2021, 43, 1039-1051.	4.6	25
4	Regional Strength of Large-Scale Functional Brain Networks is Associated with Regional Volumes in Older Adults and in Alzheimer's Disease. <i>Brain Connectivity</i> , 2021, 11, 201-212.	1.7	8
5	Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1939-1947.	3.0	13
6	Supporting and Protecting People with Dementia in the COVID-19 Pandemic. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 43-49.	2.6	2
7	Counting deficits or diseases? The agreement between frailty and multimorbidity in subjects with cognitive disturbances. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 179-182.	2.9	6
8	The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak. <i>Frontiers in Medicine</i> , 2020, 7, 552991.	2.6	2
9	Use of Biomarkers in Ongoing Research Protocols on Alzheimerâ€™s Disease. <i>Journal of Personalized Medicine</i> , 2020, 10, 68.	2.5	9
10	Facing Dementia During the COVID-19 Outbreak. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1673-1676.	2.6	143
11	Activation of Tyrosine Phosphorylation Signaling in Erythrocytes of Patients with Alzheimerâ€™s Disease. <i>Neuroscience</i> , 2020, 433, 36-41.	2.3	6
12	Frailty Index as a clinical measure of biological age in psychiatry. <i>Journal of Affective Disorders</i> , 2020, 268, 183-187.	4.1	20
13	Providing Simultaneous COVID-19â€“sensitive and Dementia-Sensitive Care as We Transition from Crisis Care to Ongoing Care. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 968-969.	2.5	35
14	Role of frailty in the assessment of cognitive functioning. <i>Mechanisms of Ageing and Development</i> , 2019, 181, 42-46.	4.6	9
15	Estimating dementia cases amongst migrants living in Europe. <i>European Journal of Neurology</i> , 2019, 26, 1191-1199.	3.3	27
16	Race reporting and disparities in clinical trials on Alzheimerâ€™s disease: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 101, 122-128.	6.1	44
17	Parkinsonâ€™s disease among migrants in Europe: estimating the magnitude of an emerging phenomenon. <i>Journal of Neurology</i> , 2019, 266, 1120-1126.	3.6	4
18	Plasma microRNA profiling distinguishes patients with frontotemporal dementia from healthy subjects. <i>Neurobiology of Aging</i> , 2019, 84, 240.e1-240.e12.	3.1	32

#	ARTICLE	IF	CITATIONS
19	SAT0180â€¦...EVALUATION OF FRAILITY IN SJÃ–GRENâ€™S SYNDROME: CREATION OF A FRAILITY INDEX. , 2019, , .		0
20	Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimerâ€™s disease dementia. European Journal of Health Economics, 2019, 20, 343-355.	2.8	26
21	Migrants seeking help for cognitive disturbances: exploratory data from an Italian memory clinic. Neurological Sciences, 2019, 40, 857-859.	1.9	7
22	Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimerâ€™s Disease. Current Neuropharmacology, 2019, 17, 176-183.	2.9	42
23	Agreement between diseases-centered and multidimensional models of care in disadvantaged settings. European Journal of Internal Medicine, 2018, 52, e32-e34.	2.2	0
24	Mining clinical and laboratory data of neurodegenerative diseases by Machine Learning: transcriptomic biomarkers. , 2018, , .		2
25	Baseline assessment of physical frailty in neurological drug development. CNS Neuroscience and Therapeutics, 2018, 24, 1309-1310.	3.9	1
26	Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2018, 65, 455-464.	2.6	43
27	Estimating dementia cases in the immigrant population living in Italy. Neurological Sciences, 2018, 39, 1775-1778.	1.9	6
28	Mediterranean Diet and Dementia. , 2018, , 103-115.		0
29	Why Mild Cognitive Impairment Should Not Be Approached as a Disease: Reply to Iraqi and Hughes. Journal of the American Medical Directors Association, 2017, 18, 273-274.	2.5	1
30	What Drives Country Differences in Cost of Alzheimerâ€™s Disease? An Explanation from Resource Use in the GERAS Study. Journal of Alzheimer's Disease, 2017, 57, 797-812.	2.6	23
31	Sex and gender differences in the treatment of Alzheimerâ€™s disease: A systematic review of randomized controlled trials. Pharmacological Research, 2017, 115, 218-223.	7.1	80
32	Inappropriate Sexual Behaviors Among Community-Dwelling Patients with Dementia. American Journal of Geriatric Psychiatry, 2017, 25, 365-371.	1.2	11
33	The sterile controversy on the amyloid cascade hypothesis. Neuroscience and Biobehavioral Reviews, 2017, 83, 472-473.	6.1	11
34	Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes. Dementia and Geriatric Cognitive Disorders Extra, 2017, 7, 87-100.	1.3	36
35	Need to Recalibrate Research Outcomes in Alzheimer's Disease: Focus on Neuropsychiatric Symptoms. Journal of the American Geriatrics Society, 2017, 65, 2071-2073.	2.6	8
36	How useful is the EQ-5D in assessing the impact of caring for people with Alzheimerâ€™s disease?. Health and Quality of Life Outcomes, 2017, 15, 16.	2.4	27

#	ARTICLE	IF	CITATIONS
37	The Impact of Frailty on the Risk of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: Evidences from a 5-Year Observational Study. <i>Frontiers in Medicine</i> , 2017, 4, 178.	2.6	21
38	Spontaneous Reversion of Clinical Conditions Measuring the Risk Profile of the Individual: From Frailty to Mild Cognitive Impairment. <i>Frontiers in Medicine</i> , 2017, 4, 184.	2.6	13
39	Promoting the Assessment of Frailty in the Clinical Approach to Cognitive Disorders. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 36.	3.4	30
40	External Validity of Randomized Controlled Trials on Alzheimer's Disease: The Biases of Frailty and Biological Aging. <i>Frontiers in Neurology</i> , 2017, 8, 628.	2.4	19
41	Progression of Extrapyrarnidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1085-1093.	2.6	20
42	PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 353-357.	2.6	15
43	Sundowning in Dementia: Clinical Relevance, Pathophysiological Determinants, and Therapeutic Approaches. <i>Frontiers in Medicine</i> , 2016, 3, 73.	2.6	56
44	Nutrition and Dementia: Evidence for Preventive Approaches?. <i>Nutrients</i> , 2016, 8, 144.	4.1	57
45	Predicting the Rate of Cognitive Decline in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 237-242.	1.3	17
46	Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2016, 28, 247-259.	1.0	35
47	Mild behavioral impairment: Ethical, methodological and clinical reflections. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 69, 402-403.	6.1	14
48	Are we really tackling the "evidence-based medicine issue" in Alzheimer's disease?. <i>European Journal of Internal Medicine</i> , 2016, 35, e29-e30.	2.2	11
49	Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 943-948.	2.5	128
50	How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease? suggestions from the GERAS observational study. <i>BMC Medical Research Methodology</i> , 2016, 16, 83.	3.1	13
51	SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 771-776.	2.6	14
52	Cognitive reserve and the risk for Alzheimer's disease: a longitudinal study. <i>Neurobiology of Aging</i> , 2015, 36, 592-600.	3.1	38
53	From Evidence to Action: Promoting a Multidimensional Approach to Mild Cognitive Impairment. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 710-711.	2.5	20
54	Neuropsychological predictors of rapidly progressive Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 132, 417-422.	2.1	13

#	ARTICLE	IF	CITATIONS
55	Determinants of societal costs in Alzheimer's disease: GERAS study baseline results. <i>Alzheimer's and Dementia</i> , 2015, 11, 933-945.	0.8	62
56	Sociodemographic and Clinical Changes Over Time of Individuals Evaluated for Cognitive Disturbances: Good or Bad News?. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 1095-1096.	2.5	2
57	Binge eating and fast cognitive worsening in an early-onset bvFTD patient carrying C9ORF72 expansion. <i>Neurocase</i> , 2015, 21, 543-547.	0.6	2
58	Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours. <i>Journal of Nutrition, Health and Aging</i> , 2014, 18, 677-684.	3.3	76
59	A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects. <i>Journal of Neuroinflammation</i> , 2014, 11, 30.	7.2	42
60	Issues about the use of subjective cognitive decline in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2014, 10, 881-882.	0.8	16
61	Familial Alzheimer's disease sustained by presenilin 2 mutations: Systematic review of literature and genotype-phenotype correlation. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 42, 170-179.	6.1	37
62	Caregiver Burden in Alzheimer's Disease: Differential Associations in Adult-Child and Spousal Caregivers in the GERAS Observational Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 51-64.	1.3	77
63	Efficacy of sertraline in a patient with Neuro-Behçet's disease. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 896-897.	1.5	4
64	Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. <i>Biological Psychiatry</i> , 2013, 74, 384-391.	1.3	105
65	Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study. <i>Journal of Neurology</i> , 2013, 260, 1859-1865.	3.6	35
66	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. <i>Neurobiology of Aging</i> , 2013, 34, 1711.e7-1711.e13.	3.1	43
67	The GERAS Study: A Prospective Observational Study of Costs and Resource Use in Community Dwellers with Alzheimer's Disease in Three European Countries - Study Design and Baseline Findings. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 385-399.	2.6	129
68	Restless Legs Syndrome in a Group of Patients With Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 165-170.	1.9	18
69	Rivastigmine in the Treatment of Hypersexuality in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 287-288.	1.3	14
70	Behavioral and psychological subsyndromes in Alzheimer's disease using the Neuropsychiatric Inventory. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 795-803.	2.7	86
71	Cognitive Interventions Targeting Subjective Cognitive Complaints. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 560-567.	1.9	19
72	Gender Effects on Plasma PGRN Levels in Patients with Alzheimer's Disease: A Preliminary Study. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 313-318.	2.6	17

#	ARTICLE	IF	CITATIONS
73	Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD. <i>Neurology</i> , 2012, 79, 1012-1018.	1.1	7
74	Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 745-749.	2.6	35
75	Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease. <i>Neurological Sciences</i> , 2012, 33, 201-208.	1.9	6
76	Cessation versus Continuation of Galantamine Treatment after 12 Months of Therapy in Patients with Alzheimer's Disease: A Randomized, Double Blind, Placebo Controlled Withdrawal Trial. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 211-220.	2.6	32
77	Presenilin 2 mutation R71W in an Italian early-onset sporadic Alzheimer's disease case. <i>Journal of Neurology</i> , 2011, 258, 2043-2047.	3.6	6
78	Serotonin toxicity: a short review of the literature and two case reports involving Citalopram. <i>Neurological Sciences</i> , 2011, 32, 507-509.	1.9	26
79	Prosodic Impairment in Alzheimer's Disease: Assessment and Clinical Relevance. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E21-E23.	1.8	14
80	A Novel Mutation in the Predicted TMIII Domain of the PSEN2 Gene in an Italian Pedigree with Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 43-47.	2.6	19
81	The London APP Mutation (Val717Ile) Associated with Early Shifting Abilities and Behavioral Changes in Two Italian Families with Early-Onset Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 484-490.	1.5	13
82	Effect of citalopram in treating hypersexuality in an Alzheimer's Disease case. <i>Neurological Sciences</i> , 2008, 29, 269-270.	1.9	49
83	A descriptive study on constructional impairment in frontotemporal dementia and Alzheimer's disease. <i>European Journal of Neurology</i> , 2008, 15, 589-597.	3.3	21
84	Contribution of right hemisphere to visual imagery: A visual working memory impairment?. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 902-911.	1.8	14
85	Causes of cross-over in unilateral neglect: between-group comparisons, within-patient dissociations and eye movements. <i>Brain</i> , 2005, 128, 1386-1406.	7.6	50
86	A case-control study on Alzheimer's disease and exposure to anesthesia. <i>Neurological Sciences</i> , 2002, 23, 11-14.	1.9	116
87	Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2000, 120, 65-75.	4.6	57
88	Bilateral simultaneous cerebellar infarction in the medial branches of the posterior inferior cerebellar artery territories. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 433-436.	0.1	13
89	Buspiron, Parkinson's Disease, and the Locus Coeruleus. <i>Clinical Neuropharmacology</i> , 1986, 9, 373-378.	0.7	58
90	GABA-Agonist Therapy for Alzheimer's Disease. <i>Clinical Neuropharmacology</i> , 1986, 9, 257-263.	0.7	40

#	ARTICLE	IF	CITATIONS
91	Muscarinic Agonist Therapy of Alzheimer's Disease. Archives of Neurology, 1986, 43, 659.	4.5	91
92	Caerulein Treatment of Parkinson's Disease. Clinical Neuropharmacology, 1985, 8, 266-270.	0.7	5
93	Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours. Journal of Nutrition, Health and Aging, 0, , .	3.3	9